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Abstract
Mannheimia haemolytica-induced bovine respiratory disease causes loss of millions of dollars to Canadian cattle
industry. Current antimicrobials are proving to be ineffective and leave residues in meat. Antimicrobial peptides
(AMPs) may be effective against M. haemolytica while minimizing the risk of drug residues. Cationic AMPs can kill
bacteria through interactions with the anionic bacterial membrane. Human β-Defensin 3 (HBD3) and microcin J25
(MccJ25) are AMPs with potent activity against many Gram-negative bacteria. We tested the microbicidal activity
of wild-type HBD3, three HBD3 peptide analogues (28 amino acid, 20AA, and 10AA) derived from the sequence of
natural HBD3, and MccJ25 in vitro against M. haemolytica. Three C-terminal analogues of HBD3 with all cysteines
replaced with valines were manually synthesized using solid phase peptide synthesis. Since AMPs can act as chemoattractant we tested the chemotactic effect of HBD3, 28AA, 20AA, and 10AA peptides on bovine neutrophils in Boyden
chamber. Minimum bactericidal concentration (MBC) assay showed that M. haemolytica was intermediately sensitive
to HBD3, 28AA and 20AA analogues with an MBC of 50 µg/mL. The 10AA analogue had MBC 6.3 µg/mL which is likely
a result of lower final inoculum size. MccJ25 didn’t have significant bactericidal effect below an MBC < 100 µg/mL.
Bovine neutrophils showed chemotaxis towards HBD3 and 20AA peptides (P < 0.05) but not towards 28AA analogue.
Co-incubation of neutrophils with any of the peptides did not affect their chemotaxis towards N-formyl-l-methionyll-leucyl-phenylalanine (fMLP). The data show that these peptides are effective against M. haemolytica and are chemotactic for neutrophils in vitro.
Keywords: HBD3, Microcin J25, Cationic anti-microbial peptides, Solid phase peptide synthesis (SPPS), Bovine
neutrophils, Chemotaxis
Introduction
Cattle industry is a major contributor to global economy
and is expected to play a critical role in meeting nutritional needs of expanding middle classes in emerging
economies such as China and India. For example, Canada
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has nearly 83 000 cattle farms and ranches and this sector contributes upwards of $20 billion a year to Canadian
economy [1]. The beef and dairy cattle industry suffer
significant economic losses due to Mannheimia haemolytica-induced Bovine respiratory disease (BRD) [2]. M.
haemolytica, a Gram-negative coccobacillus that causes
pneumonia in cattle, resides in the nasopharynx of cattle in a commensal relationship, but stress and viral infections compromise host defenses giving M. haemolytica
an opportunity to invade lungs and cause infection [3].
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A variety of vaccines and antibiotics against M. haemolytica are available but control and prevention are still a
problem and due to which approximately $1 billion per
year are lost by the US cattle industry [2–6] with similar relative losses in other countries such as Australia and
Canada [7]. There is a growing evidence of development
of resistance in M. haemolytica against commonly used
antimicrobials and a call to take quick steps to develop
new and effect anti-microbials to combat this pathogen
[8, 9]. Problems such as antibiotic resistance, antibiotic
residue in meat and an inadequacy of vaccines push for
the search of alternative treatments.
In this context, antimicrobial peptides (AMPs) have
received significant attention as alternatives to antibiotics
[10, 11]. Human β-Defensin 3 (HBD3) has been isolated
from airways surface fluid from patients with psoriasis,
suggesting it may play a role in fighting local infection
[12]. Recent work by the Caswell laboratory has shown
that treatment with naturally expressed Tracheal Antimicrobial Peptide, a defensin, neither killed M. haemolytica
nor prevented the development of lung disease [13, 14].
Coupled with the fact that M. haemolytica, in normal
condition, is prevented from entering into the lungs by
the host’s innate defense mechanism which includes the
bovine defensins [3], it was thought that HBD3 peptide
might be effective in M. haemolytica-induced pneumonia. Microcins are another class of AMPs which are
produced by bacteria such as E. coli. Microcins inhibit
the growth of many pathogenic Gram-negative bacteria
with Minimum inhibitory concentration (MIC), in the
nanomolar range [11, 15–20]. Specifically, MicrocinJ25
(MccJ25) is a peptide comprised of 21 amino acids and
is active against many Gram-negative bacteria such as
Escherichia coli and Salmonella [21]. Mccj25 is stable
in the presence of many proteolytic enzymes because of
its unique lasso like structure [11]. Considering the economic impact of M. haemolytica infections in cattle and
lack of effective anti-microbial peptides to replace antibiotics, we hypothesize that HBD3 and MccJ25 might
prove as potential candidates for application in the treatment of BRD. The objective of the current study was to
design, synthesize, purify and evaluate the antimicrobial
activity of HBD3, its analogues, and recombinant MccJ25
against M. haemolytica.

Materials and methods
Expression and purification of microcin J25

Wild-type Microcin J25 (MccJ25) was used in this study
as formation of the lasso ring is not possible synthetically.
The peptide was expressed using MccJ25 biosynthetic
gene cluster carrying plasmid pTUC202 (a gift from Rutgers University USA) in competent E. coli MC4100 cells
[25]. It was grown in 2L M9 minimal media for 18 h at
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37 °C. The culture supernatant was obtained by centrifugation at 4000 g for 15 min, and then subjected to two
successive purification steps. First, it was applied on the
flex column filled with XAD16 resin (Sigma-Aldrich,
St. Louis, USA). Two successive elution steps were performed with (30:70, v/v) and (80:20, v/v) methanol/water
mixtures. MccJ25 is eluted in the (80:20, v/v) methanol/
water mixture. MccJ25 was purified using reversed-phase
(RP) HPLC (Varian Prostar 210, SpectraLab Scientific
Inc. Markham, Canada). The purity of the peptides was
confirmed by MALDI-TOF mass spectrometry.
Synthesis and purification of HBD3 analogues

HBD3 fragments were synthesized manually on 2-chlorotrityl chloride resin (0.2 mmol, 1 mmol/g) following the
standard Fmoc solid phase peptide synthesis (SPPS) [22].
The first amino acid was coupled using DIPEA for 5 h.
Further amino acids were coupled at twofold excess using
HCTU/HOBT/NMM as activating mixture in DMF.
Amino acid coupling was performed for 3 h at room temperature to ensure the completeness of the reaction, followed by Fmoc group deprotection using piperidine in
DMF. These two reactions were repeated until assembly
of the peptide was complete. A Kaiser test was performed
after coupling of each amino acid. After completion of
the synthesis, peptides were cleaved from the resin and
all protecting groups were removed using cleavage mixture at room temperature. Cleaved peptide was concentrated by rotary evaporation. Cold ether was added to
precipitate the peptide and crude peptide was isolated
after centrifugation. Crude peptides were dissolved in
water and purified using RP-HPLC (Varian Prostar 201).
The purity of the peptides was confirmed by RP-HPLC
and MALDI-TOF mass spectrometry.
Antimicrobial activity testing of peptides

Wild-type HBD3, its analogues, and MccJ25 were tested
against M. haemolytica-A1 using optical density method
and colony count assay. Briefly, an aliquot (5 µL) from
bacteria suspension stored at −80 °C was put in 5 mL
BHI broth at 37 °C for 18 h. An aliquot (10 µL) from this
overnight culture was added to fresh BHI broth and incubated at 37 °C for a further 5 h to obtain mid-log phase
bacteria. The culture was then centrifuged for 10 min
at 800 g at 4 °C. The supernatant was discarded and the
bacterial pellet was resuspended in cold, sterile sodium
phosphate buffer (SPB) and washed again at 800g for
10 min at 4 °C. The pellet was resuspended in 5 mL SPB.
To calculate the number of CFU/mL in the 5 h culture,
six successive tenfold dilutions were made. From the last
dilution 100 µL was plated in duplicate on petri dishes
containing BHI agar and incubated for 24 h. After 24 h
the colonies were counted in the two petri dishes and
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then averaged. Total number of colonies was the average
number of colonies multiplied by the dilution factor.
All assays were carried out in sterile 96-well polypropylene flat-bottomed plates using a broth microdilution
method. Two-fold serial dilutions of peptide were made
in SPB, and 50 µL of each concentration of peptide was
added to the wells of the assay plate. Fifty µL (25 000
cells) of the bacterial suspension adjusted to 5 × 105 cfu/
mL in incubation media was prepared by adding 200 µL
of BHI broth in 6.8 mL SPB and added to each well. Positive control wells contained 50 µL of the bacteria with
50 µL of 64 µg/mL ampicillin and negative control wells
contained 50 µL of SPB and 50 µL bacterial suspension.
Sterility control well contained 100 µL BHI broth to test
and ensure that broth was not contaminated.
The plates were sealed with aluminum foil and were
incubated at 37 °C for 2 h then 50 µL of the contents of
the well were pipetted on BHI agar plates and incubated
for 24 h. The bactericidal activity was expressed as the
MBC which is the concentration at which 99.9% of the
colonies are killed and the Lethal dose 50 (LD50) at which
50% or more bacteria are killed [23–25]. All experiments
were run in triplicates.
Polymorphonuclear cell isolation and chemotaxis assay
Polymorphonuclear cell isolation

Neutrophils were isolated from cattle using established
methods and approved by the University of Saskatchewan’s Committee on Animal Care [26]. For each individual animal, blood was pooled into 50 mL tubes and
diluted with an equal volume of PBS then 12.5 mL of
the diluted blood was layered over 10 mL of Ficoll Paque
PLUS (Sigma-Aldrich, St. Louis, USA) while taking care
to preserve the interface between the two liquids. Following centrifugation at 400 g for 30 min at 20 °C with
the brake turned off, the lymphocyte layer was discarded
along with Ficoll and plasma. The pellet was washed in
20 mL PBS with centrifugation at 500 g with low brake
for 10 min. The supernatant was discarded and the pellet was suspended in equal volume of sterile water and
gently mixed for 20 s followed by addition of equal volume of 1.8% NaCl to restore tonicity. The mixture was
centrifuged at 500 g for 10 min and followed by another
washing and centrifugation at 4 °C. The resulting neutrophil pellet was resuspended in PBS. Bovine neutrophils,
collected in the above manner had more than 92% purity,
and their viability was greater than 95% based on Trypan
blue exclusion assay. Therefore, we use the term neutrophils in the manuscript.
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lower compartment wells of a 48-well Boyden Chamber.
After the fMLP loading, the polycarbonate membrane filter (pore size 5 μM), with the shiny side up, was placed
over the lower chamber. Next, silicone gasket was placed
on the membrane, then the upper chamber was put on
top of the gasket and the lug nuts firmly secured. Cell
suspension (1 × 106 cells) was then placed over control
wells and N/P wells (neutrophil at top and peptide in the
bottom wells). The whole assembly was then incubated
at 37 °C in humidified air with 5% C
 O2 for 20 min. After
the incubation, the Boyden chamber was disassembled
and the membrane carefully held with the bulldog clamp
and the cells on the upper shiny surface scraped with the
wiper blade. Next, the filter membrane was stained with
the Diff-Quick and mounted on glass slide with the bottom side up. The cells within the filter pores were then
counted in five random fields under light microscope at
40×. The results are presented as the number of migrated
neutrophils per microscopic field.
Migration inhibition assay

Since peptides can be immunomodulatory, migration
inhibition was carried out to determine if the peptides
inhibit neutrophil migration. This assay was performed in
the same manner as the chemotaxis assay with the only
difference being that peptide and neutrophils were incubated together on the top of the filter; 25 μL of 100 μg/
mL peptide and 25 μL (2 × 106 cells) of neutrophils were
put together. In the lower wells 25 μL of 114 nM fMLP
(chemoattractant) was placed followed by the staining
and counting of the cells as described above.
Statistical analysis

Data from susceptibility testing assay was analyzed
using the non-parametric statistics (using ranked data),
because the data were variable among groups most likely
due to small sample size. The comparisons were done
using contrasts (1 compared to 2, 2 compared to 3, and
so on), given that we expected a decrease in colony count
with increasing concentrations. Groups were considered
statistically significant if the P-value was less than 0.05.
A One-way ANOVA followed by Dunnets Multiple Comparisons test was performed on data obtained from the
chemotaxis and migration inhibition assay. Significance
was recorded when P < 0.05. Computer software GraphPad Prism 6 and SPSS (GraphPad Software, San Diego,
USA) for migration and susceptibly assays, respectively,
were used.

Results

Chemotaxis assay

Peptide design and synthesis

We used fMLP (114 nm) as the chemoattractant.
Approximately 25 μL of peptides (50 μg/mL) was put into

Five peptides, HBD3, 28AA HBD3, 20AA HBD3, 10AA
HBD3, and Microcin J25 (MccJ25) were evaluated in this
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study. Because wild type HBD3 is commercially available, we purchased it at 95% purity (AnaSpec Inc.). The
amino acid sequences of the HBD3 and its analogues and
MccJ25 studied are shown in Figure 1.
Approximately 3 mg Wild-type MccJ25 was obtained
by over expression protocol already established by Soudy
et al. [27]. After purification by flex column the crude
MccJ25 was finally purified with the C-18 RP-HPLC, at
a flow rate of 2 mL/min 55–80% methanol/water mixture in 55 min. Various fractions at different time points
were obtained. Fraction containing the desired mass
for MccJ25 eluted at 20 min on the RP-HPLC column
(Additional File 1). The calculated mass for MccJ25 was
2107 MW and the mass was determined to be [M + H]+
2107.7 (Additional File 1). The elute from desired peak
was collected, pooled and lyophilized. The yield or the
concentration of MccJ25 was measured using UV–Vis
spectrophotometer at 278 nm.
SPPS synthesis of HBD3 analogues

Three C-terminal HBD3 analogues were designed as
short fragments of wtHBD3 with different amino acid
chain lengths (Figure 1). In each analogue, cysteine was
replaced with valine to remove di-sulfide linkages and
render the fragment linear and more stable. Standard
SPPS with Fmoc chemistry was used for the synthesis of
the three analogues. Manual SPPS was carried out in a
reaction vessel starting with the shorter 10AA analogue.
Amino acid chain was built on 2-chlorotrityl resin in the
reaction vessel. The proper peptide chain elongation was
ensured with Ninhydrin test after every coupling step and
test cleavage after every third amino acid. After building
10AA amino acid chain, the peptide was cleaved from
the solid support or resin. A treatment with 95% TFA, 5%
tri-isopropylsilane in water, for 2 h at room temperature
with continuous shaking of the vessel was used to simultaneously de-protect the side chains and cleave the crude
peptide from the resin. On a semi-preparative RP-HPLC
column using gradient elution, 22 mg of the crude 10AA
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analogue was purified. A gradient method with 10–35%
acetonitrile/water in 60 min with a flow rate of 1.3 mL/
min was used on the RP-HPLC for the purification of
crude synthetic peptide 10 AA.
Peaks eluted at 10.9–11.2, 13.4–14.5, 17–18, 26–27,
27–28, and 33–34 min were collected. Mass spec,
through MALDI-TOF with α-cyano-4-hydroxycinnamic
acid (HCCA) as a matrix, for all of the elutions was taken
and elution at peak 13.4–14.5 had the correct mass. Calculated mass for 10AA was 1283 and the mass found was
[M + H]+ 1282.6. (Additional file 7).
20AA analogue was synthesized in a manner similar to
10AA analogue. Beyond the addition of tenth amino acid,
ninhydrin test and test cleavage were performed after
every third coupling. Double coupling was performed for
the last four amino acids, because of the positive ninhydrin test after single coupling. The purification scheme
used for 20AA analogue was the same as the 10AA analogue. Peaks eluted at 13–14.5, 23–25, 29–30, 35–36.5,
and 51.5–53 min were collected. Similarly, the MALDITOF mass spectrum for all of the elutions was taken and
the correct mass was found in elution at peak 35–36.5
(Additional file 3). Calculated mass for 20AA was 2384
and the mass found was [M + H]+ 2383.3 (Additional
file 3). However, complete resolution between 19AA analogue and 20AA analogue could not be achieved. Several
other HPLC gradient were tried to achieve resolution of
20AA analogue from other truncated peptides but best
results were achieved with 10–35% acetonitrile/water in
60 min with a flow rate of 1.3 mL/min scheme. Nonetheless, the major component from the eluate was 20AA
analogue and 19AA analogue was only a small fraction.
Overall 24–28 mg of purified peptide was obtained.
The synthesis of 30AA, linear with all cysteines
mutated with valine, was attempted. However, the chain
could be elongated only up to 28 AA analogue as identified by mass spec of crude peptide showing a mass of
3386.4 [M + H]+ (Calculated 3387) (Additional file 4).
The coupling of arginine to the 28th amino acid valine

Figure 1 Amino acid sequences of HBD3, and the three HBD3 fragments. Substitution of cysteine residues with valine in the fragments is
shown in red.
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could not be achieved even with three consecutive couplings. Since the manual synthesis of such a long amino
acid chain is usually fraught with many pitfalls, the elongation of a 28 amino acid chain was a satisfactory result,
because the appropriate balance of positive charge and
hydrophobicity was attained.
Microbicidal effect of peptides

Peptides HBD3, its analogues and Mccj25 were assessed
for Minimum bactericidal concentration (MBC). MBC is
described as the lowest concentration of each drug that
resulted in a 99.9% reduction in CFU of the initial inoculum. All the peptides have shown intermediate to potent
killing activity towards M. haemolytica (Figures 2, 3). The
final inoculum size should be 5 × 105 cfu/mL, but varied
between 1 × 105 and 1 × 106 cfu/mL and is acceptable as
per M7-A7 guidelines. However, some published studies
have taken final inoculum in the range of 1 04–105 cfu/mL
[28].
The comparison of antibacterial activity at different
concentrations of HBD3 revealed that HBD3 was equally
active at 100.0 µg/mL and 50.0 µg/mL. However, the concentrations 50 µg/mL and 25.0 µg/mL, 25.0 µg/mL and

Figure 3 Comparisons between microbicidal effects of eight
different concentrations of MccJ25. Comparisons were performed
using contrasts for example 100.0 μg/mL was compared to 50.0 μg/
mL, 25.0 μg/mL compared to 12.5 μg/mL employing non-parametric
statistics (ranked data). Statistical significance between two
concentrations is indicated by *P < 0.05 and **< 0.01. The data are
represented as Mean ± SEM.

12.5 µg/mL, 12.5 µg/mL and 6.3 µg/mL, and 6.3 µg/mL
and 3.1 µg/mL were statistically different. The concentrations 3.1 µg/mL and 0.8 µg/mL were not active and there

Figure 2 Comparisons between microbicidal effects of eight different concentrations of HBD3 and HBD analogues. Comparisons were
performed using contrasts for example 100.0 μg/mL was compared to 50.0 μg/mL, 25.0 μg/mL compared to 12.5 μg/mL employing non-parametric
statistics (ranked data). Statistical significance between two concentrations is indicated by *P < 0.05 and **< 0.01. The data are represented as
Mean ± SEM.
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was no statistical difference between them (Additional
file 7 and Figure 2A).
The activity of 10AA at all the concentrations was similar without any statistical difference. It is worth noting
that this is observed only with 10AA analogue which is
very likely due to a smaller inoculum size (104 cfu/mL)
used (Additional file 8 and Figure 2B). Similar to HBD3,
20AA analogue was equally active at both 50.0 µg/mL
and 100.0 µg/mL. However, the concentrations 50.0 µg/
mL and 25.0 µg/mL, 25.0 µg/mL and 12.5 µg/mL,
12.5 µg/mL and 6.3 µg/mL, and 6.3 µg/mL and 3.1 µg/mL
were statistically different from each other. Again, concentrations 3.1 µg/mL and 0.8 µg/mL were not active and
there was no statistical difference among them (Additional file 9 and Figure 2C).
The antibacterial effect of 28AA analogue’s concentrations 100.0 µg/mL to 6.3 µg/mL was statistically similar
as was the antibacterial effect for the concentrations 3.1–
0.8 µg/mL. The only difference was observed between
3.1 and 6.3 µg/mL (Additional file 10 and Figure 2D and
Additional file 3). Additional file 3 shows a clear dose
response when M. haemolytica was treated with crude
28AA analogue. The number of colony forming units
progressively increased with decreasing peptide concentration. The MBC and LD50 of all the peptides have been
compared (Table 1). While HBD3 and HBD3 20AA analogues have equal MBC values of 50 µg/mL, MBC value
for HBD3 28AA analogue was the lowest at 12.5 µg/mL,
and MccJ25 had highest MBC value of 100 µg/mL (Additional file 10). Nearly comparable LD50 values do not
effectively discriminate different peptides. However, the
value of LD50 is apparent in the fact that it shows MccJ25
kills half of the bacterial population at 6.3 µg/mL.
MccJ25 exhibited microbicidal effect; however, the
reduction in colony count was much less in comparison
to other peptides Different concentrations of MccJ25
were compared for antibacterial activity against M.
haemolytica but no statistically significant difference was
observed (Additional file 11 and Figure 3).

Chemotaxis assay

HBD3 is chemotactic for human neutrophils [29]. The
chemotaxis of bovine neutrophils in response to HBD3,
HBD3 20AA analogue, and HBD3 28AA analogue
at 50.0 μg/mL was studied. Neutrophil migration in
response to HBD3 and 20AA analogue was found to be
statistically significant when compared with PBS (Negative control), but the difference between PBS and 28AA
was not significant (Figure 4). The result shows that
HBD3 and HBD3 20AA analogue were chemotactic for
bovine neutrophils at 50.0 μg/mL where as 28AA analogue was not.
Migration inhibition assay

Bovine neutrophils were treated with 50.0 μg/mL of
HBD3, HBD3 20AA analogue, and HBD3 28AA analogue and the effect of peptides on neutrophil migration towards fMLP was studied. Neutrophil migration
towards fMLP when neutrophils were incubated with
HBD3, HBD3 20AA analogue, and HBD3 28AA analogues was statistically different from the PBS, which
shows that none of the peptides inhibited migration of
neutrophils towards fMLP (Figure 5).

Discussion
To our knowledge, this is the first study to show that
based on MBC and LD50 data HBD3 and its analogues
and MccJ25 peptides kill M. haemolytica in vitro. In addition, the peptides are chemotactic for the bovine neutrophils. These data are important considering the economic
impact of morbidity and mortality associated with BRD

Table 1 Comparisons of MBC and LD50 of the peptides
Peptide

MBC (μg/mL)

HBD3 10AA analogue

6.3

HBD3 20AA analogue

50.0

LD50 (μg/mL)
≥ 3.1
3.1

HBD3 28AA analogue

12.5

3.1

HBD3

50.0

6.3

> 100.0

6.3

MccJ25

MBC (Minimum Bactericidal Concentration) is the concentration of antibiotic
at which 99.9% of the CFU in the final inoculum are killed and LD50 is the lethal
dose for ≥ 50% of bacteria.

Figure 4 Chemotaxis assay of the peptides against bovine
neutrophils. Number of neutrophils that migrated in response to
HBD3, HBD3 20AA analogue and, HBD3 28AA analogue after 20 min
incubation at 37 °C. The three peptides were used at a concentration
of 50.0 μg/mL. fMLP is the positive control. Mean ± SEM of three
independent experiments. One way ANOVA was followed by
Dunnett’s multiple comparison test (P ≤ 0.0036). Asterisks show
significant difference from PBS (Negative control) *P < 0.05.
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caused by M. hemotlyica. The development and use of
antimicrobial peptides may also provide us with tools to
reduce the use of antibiotics and thus reduce the threat of
anti-microbial resistance and their residues in meat.
HBD3 and MccJ25 were selected as potential candidates. Wild-type HBD3 with purity ≥ 95% was commercially obtained, whereas MccJ25 was expressed in E.
coli followed by purification and characterization. The
data contained in this study show synthesis and characterization of three analogues of HBD3. We successfully
synthesized HBD3 analogues (Figure 1) namely 10AA,
20AA but couldn’t synthesize 30AA using Fmoc-SPPS.
During SPPS, the -amino acid chain could be elongated
up to only 28AA as confirmed by MALDI-TOF even after
repeated coupling. Mass spectrometry of 28AA crude
peptide shows other peaks along with 28AA analogue
peak suggesting impurities in the crude peptide. The
crude peptides (MccJ25, 10AA and 20AA analogue) were
purified by RP-HPLC and then by MALDI-TOF mass
spectrometry to confirm mass of the crude and pure
peptides.
In vitro susceptibility tests for cationic peptides are
challenging to perform because polycationic peptides
tend to precipitate and bind to the anionic surface of
bacterial cells and plastic surface. There are data on the
comparison of two methods for evaluating the in vitro
antimicrobial activities of cationic AMP’s [30]. The comparative data showed that NCCLS protocol gave MICs

Figure 5 Effect of peptides on neutrophil migration towards
fMLP. Number of neutrophils that migrated towards fMLP (114 nM)
after 20 min incubation at 37 °C. Neutrophils were treated with
50.0 μg/mL HBD3, HBD3 20AA analogue and, HBD3 28AA analogue.
pn/f stands for peptide and neutrophils together in the upper
well and fmlp in the bottom during 20 min incubation. fMLP is the
positive control. Mean ± SEM of three independent experiments. One
way ANOVA was followed by Dunnett’s multiple comparison test
(P ≤ 0.0036). Asterisks show significant difference from PBS (Negative
control) *P < 0.05.
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and MBCs values that were four times higher than the
method proposed by Hancock [30]. We used the 96-well
plates for antimicrobial evaluation to reduce the possibility of false higher MBCs and MICs as apparent in the
results of Giacometti and the results of our preliminary
MIC experiment (data not shown). However, we used
the NCCLS definition of MBC which is the lowest concentration of each drug that resulted in a 99.9% reduction in CFU of the initial inoculum whereas the Hancock
method defines the MBC as the lowest concentration of
each drug that prevented any residual colony formation.
In addition to the MBC, we also carried out the MIC
assays. This classification of peptide potency however is
arbitrary, “a strain was defined as sensitive to the peptide
if MBC levels were < 10 μg/mL, as intermediately sensitive if MBC levels were 10–100 μg/mL, or as resistant at
MBC levels of > 100 μg/mL” [28].
In our study, HBD3 was highly effective in killing M.
haemolytica with MBC value of 50 μg/mL. The testing of
the bactericidal activity of the HBD3 against 28 species
and 55 strains of Gram-positive cocci and Gram-negative
fermentative and non-fermentative rods showed it be
intermediately or highly effective [28]. However, MBC
value in our study is higher when compared to the data
from Sahly et al. in which only three strains out of 55
tested showed intermediate susceptibility (MBC value of
50.0 μg/mL), whereas rest of the strains were highly sensitive to HBD3 with MBC’s ranging from 0.1 to 6.3 μg/
mL [28]. The reason for lower MBC’s in their study could
be attributed to use of a lower final bacterial inoculum
of 104 to 105/mL [28] compared 105 to 106/mL used in
our study. This phenomenon of lower MBC corresponding with low final inoculum size was also observed in
our data from 10AA analogue. We tested various concentrations of this analogue with final inoculum size of
104 cells/mL of M. haemolytica and this gave us MBC of
6.3 μg/mL.
HBD3 analogues showed intermediate activity against
M. hemolytica. 20AA analogue was active against M.
haemolytica in the same concentration as the wild type
HBD3, after averaging results from three different experiments, in duplicates, they showed equivalent MBC
values. 20 AA analogue’s potent activity is likely attributable to its high positive charge (+9). HBD has a higher
positive charge of +11 but showed anti-microbial activity similar to that of 20AA analogue. Therefore, it will
be interesting to replace a couple of positively charged
basic polar amino acids such as arginine or lysine with
valine, a neutral nonpolar amino acid, to the analogue
more hydrophobic and increasingly selective for bacterial
membranes. This argument is further supported by the
fact that 10 AA analogue with +7 charge displayed excellent activity against M. haemolytica with 6.3 μg/mL MBC
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when used with a small inoculum. The testing of this analogue with a higher bacterial inoculum, similar to other
peptides, would have further bolstered our results. Nevertheless, MBC of 10AA analogue was lower than both
HBD3 and 20AA analogue and therefore we may be able
extrapolate this result for higher inoculum size.
Zhou et al. made eight C-terminal 10AA analogues of
HBD3 replacing cysteines with either Valine, Tryptophan
or Tyrosine. Out of these, Valine was easier to build via
SPPS synthesis and was found to be most active and it
also didn’t affect antimicrobial activity against bacteria
such as Pseudomonas aeruginosa [31]. Because cysteine
and methionine are prone to oxidation, they are often
replaced by hydrophobic residues such as valine [32].
They also made a dimer of Valine 10AA analogue, which
turned out to be the most potent analogue. Instead of
making a dimer of 10AA analogue, we chose to elongate
the peptide chain up to 20 and 28 AA with mutation of all
Cysteines with Valines. Both 20AA and 28AA analogues
were active with 28AA peptide showing better activity than wild-type HBD3 [31]. These researchers further
tested their peptides against Pseudomonas aeruginosa,
a Gram −ve bacteria, in the same concentration range
as ours. Comparing their study with ours, we found that
the 10AA analogue had similar MBC values (50.0 μg/mL)
for both Pseudomonas aeruginosa and M. haemolytica.
However, their dimer was more potent than our 20AA
analogue. The in vitro data also shows that removal of
disulfide bonds does not affect the antimicrobial potency
of the peptides as shown previously [29]. However, in vivo
studies are required to further establish this observation.
Studies have shown that some C-terminal (R36-K45)
analogues of HBD-3 can non-covalently dimerize to
acquire a defined structure in conditions mimicking
biological systems or on the lipid bilayer [31, 33]. Elucidating the underlying physico-chemical properties was
beyond the scope of this study. However, we can speculate
about the 3D structure of 20AA analogue based on the
nearly comparable MBC results of 20AA analogue with
wtHBD3, and findings of the previous studies performed
with NMR, fluorescence correlation spectroscopy and
molecular dynamics simulation techniques [33]. It is possible that the 20AA analogue, dimerized both in aqueous
solution and on the membrane surfaces, which tend to
localize the positive charge density which may account for
its bactericidal efficacy. Alternatively, the 20AA analogue
would just remain as a linear monomer and its potent
activity results from increased flexibility due to a loss of
secondary structure. It also is possible that the activity of
20AA analogue could be due to truncated peptide (19AA)
that coeluted during purification of the peptide and was
used.
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MccJ25 kills bacteria by inhibiting the RNA Polymerase (RNAP) but this microcin peptide has to enter
the bacterial cell to accomplish this action. The MccJ5
sensitive strains have the transporter proteins such as
outer-membrane protein FhuA and the inner membrane
protein SbmA to facilitate the transport of the antimicrobial peptides into the cells [34, 35]. There are some data
on the characterization of outer membrane proteins of M.
haemolytica [36, 37] but we don’t know whether specific
membrane proteins exist to facilitate transport of MccJ25.
Furthermore, MccJ25 is not effective against many bacteria of the family Enterobacteriaceae that are not related to
the MccJ25 producing members [38]. It could be argued
that MccJ25 shows a narrow action spectrum activity
in vitro but could be active in vivo against resistant species [38, 39]. It has been shown that resistant bacteria
become susceptible to antibiotics upon their entry into
the low pH environment in the phagolysosomes of macrophages likely due to the nonspecific MccJ25 uptake into
the bacterial cell through altered bacterial membrane
permeability. Also, MccJ25 has been shown to cause disruption of the membrane potential [39] and hence it can
be speculated that inside a macrophage M. haemolytica
could become sensitive to MccJ25.
None of the five peptides tested by us inhibited visible
growth of the M. haemolytica when compared with the
positive control. The bactericidal nature of the cationic
peptides could be the possible explanation of these results.
Ampicillin at a concentration of 24 μg/mL served as negative control in our experiments and there was no growth
in the negative wells. Since there were 10 000–25 000 bacteria/well and even if 0.1% of them survived and the peptide got consumed or deactivated over next few hours and
media was still available for their growth. It is very likely
that bacteria resumed growth to give false negatives. To
ascertain the real cause, we need to do additional timekill studies as well as testing against other serotypes of M.
haemolytica.
Anti-microbial peptides kill microbes and have immunomodulatory functions such as modulating recruitment of neutrophils [40]. Defensins such as HBD2 but
not HBD1 have been shown to be chemotactic for human
neutrophils pre-treated with TNF-α but not normal
in vitro [35]. Our data show HBD3 and its 20AA analogue
to be chemotactic to control untreated bovine neutrophils. The difference in results from our experiments and
those obtained previously may be reflective of species differences. Furthermore, we used the peptides at 50.0 μg/
mL and compared to concentrations of 0–10 μg/mL in
previous studies [41]. To elucidate the chemotactic behavior of 20AA analogue it must be tested against a wide
concentration range and also for neutrophils from other
species. It was earlier reported that cysteine mutated

Dhingra et al. Vet Res

(2021) 52:83

analogues of HBD3 might lose their chemotactic activity.
It might be possible that bovine neutrophils are generally
responsive to the Cysteine mutated HBD3 analogues. The
data by Taylor et al. demonstrated the indispensability of
three cysteine disulfide bridges for chemotactic activity
[42]. They showed that HBD3 analogues lacking disulfide
bridges retained chemoattractant capability. HBD3 analogue which had cysteines replaced with alanines was
devoid of any chemotactic activity. However, the chemotactic activity was not lost when the fifth cysteine was
retained and other five were replaced. These anomalous
results could be due to variation in environmental conditions or different cell species used [42]. The chemotaxis
in 28AA analogue well and PBS well was statistically not
different. This anomaly can be accounted for if we take
into consideration that 28AA was in crude form and had
contained a few truncated peptides. Lastly, the treatment
of neutrophils with any of peptides did not affect their
migration towards fMLP. Nevertheless, there is a need
for additional experiments to understand the relationship
between structure and function of the HBD3 and its linear analogues with their chemotactic property.
Taken together, we report the engineering and synthesis
of HBD analogues and MccJ25 and report their efficacy
in killing of M. haemolytica and chemotactic properties against bovine neutrophils. Further experiments are
needed to evaluate the activity against other serotypes of
M. haemolytica, in vivo studies and cell cytotoxicity assays.
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Additional file 1. Microcin J25 characterization. A) HPLC chromatogram of crude Microcin J25 (MccJ25) showing elution of MccJ25 at 20 min
following acetonitrile/water gradient on a reversed-phase column. mAU is
a symbol for the milli-absorbance unit. B) MALDI-TOF of pure MccJ25, purified by reversed-phase HPLC, showing [M + H] + peak (observed 2107.7
and calculated. 2107). Intensity is relative abundance or signal intensity of
the ions and m/z is mass to charge ratio.
Additional file 2. HBD3 10AA analogue characterization. A) HPLC
chromatogram of crude 10AA analogue showing elution of at 13.1 min
following acetonitrile/water gradient on a reversed-phase column. mAU is
a symbol for the milli-absorbance unit. Panel B shows MALDI-TOF of pure
10AA analogue, purified by reversed-phase HPLC, showing [M + H]+ peak
(found 1282.6, calculated. 1283) (B). Intensity is relative abundance or signal
intensity of the ions and m/z is mass to charge ratio.
Additional file 3. HBD3 20AA analogue characterization. (A) HPLC
chromatogram of crude 20AA analogue showing elution at 35 min following acetonitrile/water gradient on a reversed-phase column. mAU
is a symbol for the milli-absorbance unit. (B) MALDI-TOF of pure 20AA
analogue, purified by reversed-phase HPLC, showing [M + H] + peak (found
2383.1, calculated. 2384). m/z is mass to charge ratio and Intensity is relative abundance or signal intensity of the ions.
Additional file 4. HBD3 28AA analogue characterization. Panels A
shows MALDI-TOF of crude 28AA analogue, showing [M + H] + peak (found
3386.4, calculated. 3387). m/z is mass to charge ratio and Intensity is relative abundance or signal intensity of the ions.
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Additional file 5. Characterization of microbicidal activity of HBD3 28
AA analogue. Colony forming units of M. haemolytica; that survived after
incubation with 28AA analogue at concentration 50.0 μg/mL (A), 25.0 μg/
mL (B), 12.5 μg/mL (C), 6.25 μg/mL (D), Negative control plate (E) and positive control plate (F).
Additional file 6. Gradient elution scheme for 10AA and 20AA HBD3
analogues.
Additional file 7. Number of colony forming units after treatment
with HBD3.
Additional file 8. Number of colony forming units after treatment
with HBD3 10 AA analogue.
Additional file 9. Number of colony forming units after treatment
with HBD3 20 AA analogue.
Additional file 10. Number of colony forming units after treatment
with HBD3 28 AA analogue.
Additional file 11. Number of colony forming units after treatment
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